Diamandis Peter 4
4 · Vaxxinity, Inc. · Filed May 2, 2023
Insider Transaction Report
Form 4
Vaxxinity, Inc.VAXX
Diamandis Peter
Director
Transactions
- Exercise/Conversion
Class A common stock
2023-04-26$0.57/sh+429,037$244,551→ 859,641 total - Exercise/Conversion
Class A common stock
2023-04-26$1.21/sh+46,500$56,265→ 906,141 total - Exercise/Conversion
Stock option (right to buy)
2023-04-26−429,037→ 99,009 totalExercise: $0.57Exp: 2031-03-01→ Class A common stock (429,037 underlying) - Exercise/Conversion
Stock option (right to buy)
2023-04-26−46,500→ 732,642 totalExercise: $1.21Exp: 2031-03-01→ Class A common stock (46,500 underlying)
Holdings
- 13,824(indirect: By Spouse)
Class A common stock
- 1,099,915
Class B common stock
Footnotes (3)
- [F1]These securities are held by Kristin Diamandis, the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by Kristin Diamandis in which the Reporting Person has no pecuniary interest.
- [F2]These options are subject to a four-year vesting schedule, with 25% having vested on December 30, 2020 and the remainder vesting in thirty-six equal installments each month during the remainder of the vesting period
- [F3]These options are subject to a four-year vesting schedule, beginning on June 2, 2020, vesting in equal installments each month during the vesting period.